CD‐1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis
暂无分享,去创建一个
Y. Ishigaki | D. Koya | Y. Aso | Yuka Nakamura | Munehiro Kitada | K. Kanasaki | Y. Takagaki | Isao Usui | Jinpeng Li | Haijie Liu | Kyoko Nitta | Shaolan Li | Yuiko Mizunuma
[1] M. Haneda,et al. N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m2 , 2019, Clinical and Experimental Nephrology.
[2] Daisuke Koya,et al. Rodent models of diabetic nephropathy: their utility and limitations , 2016, International journal of nephrology and renovascular disease.
[3] Y. Ishigaki,et al. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis , 2016, Scientific Reports.
[4] R. MacIsaac,et al. Clinical predictive factors in diabetic kidney disease progression , 2016, Journal of diabetes investigation.
[5] M. Haneda,et al. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen , 2016, BioMed research international.
[6] D. Koya,et al. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition. , 2015, Kidney international.
[7] I. D. de Boer,et al. Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.
[8] Y. Ishigaki,et al. Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen , 2014, Diabetes.
[9] Takahisa Yamada,et al. Diabetic Complications in Obese Type 2 Diabetic Rat Models , 2014, Experimental animals.
[10] D. Koya,et al. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes , 2014, Front. Pharmacol..
[11] Y. Ishigaki,et al. N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition , 2014, BioMed research international.
[12] G. Russo,et al. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] R. D. de Boer,et al. Sodium restriction on top of renin–angiotensin–aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients , 2013, Journal of hypertension.
[14] Li-jun Ma,et al. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis , 2013, Kidney international.
[15] C. D. di Gioia,et al. Renal Antifibrotic Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline in Diabetic Rats , 2013, American Journal of Nephrology.
[16] D. Batlle,et al. New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy , 2012, Experimental diabetes research.
[17] A. Riches,et al. Overexpression of the natural tetrapeptide acetyl‐N‐ser‐asp‐lys‐pro derived from thymosin β4 in neoplastic diseases , 2010, Annals of the New York Academy of Sciences.
[18] S. Perlini,et al. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. , 2010, Clinical science.
[19] R. Kalluri,et al. Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors , 2007, Diabetes.
[20] J. Wdzieczak‐Bakala,et al. The tetrapeptide acetyl‐serine‐aspartyl‐lysine‐proline improves skin flap survival and accelerates wound healing , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[21] M. Haneda,et al. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. , 2006, Journal of the American Society of Nephrology : JASN.
[22] K. Isshiki,et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. , 2005, Diabetes.
[23] M. Cavasin,et al. Prolyl Oligopeptidase Is Involved in Release of the Antifibrotic Peptide Ac-SDKP , 2004, Hypertension.
[24] T. Sugimoto,et al. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. , 2003, Journal of the American Society of Nephrology : JASN.
[25] Daniel C. Marcus,et al. Age-Related Changes in Cochlear Endolymphatic Potassium and Potential in CD-1 and CBA/CaJ Mice , 2003, Journal of the Association for Research in Otolaryngology.
[26] O. Carretero,et al. Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts , 2001, Hypertension.
[27] S. Chua,et al. Spontaneous mutation in the db gene results in obesity and diabetes in CD-1 outbred mice. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.
[28] K. Clément,et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction , 1998, Nature.
[29] S. O’Rahilly,et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.
[30] Per Capita,et al. About the authors , 1995, Machine Vision and Applications.
[31] C. Grillon,et al. Involvement of thymosin β4 and endoproteinase Asp‐N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system , 1990, FEBS letters.
[32] Giuseppe Remuzzi,et al. Sodium intake, ACE inhibition, and progression to ESRD. , 2012, Journal of the American Society of Nephrology : JASN.
[33] 渋谷 和之. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice , 2005 .